The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Tumor lysis syndrome (TLS)
Publications
Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
Journal of clinical pharmacy and therapeutics 2009 Oct;34;607-10 — 2009 Oct — 607-10
Catastrophic tumour lysis syndrome following single dose of imatinib.
European journal of haematology 2009 Mar;82;244-5 — 2009 Mar — 244-5